• Citigroup reaffirms "Outperform" rating for NYSE:BSX, indicating a positive outlook despite a slight decline in its latest trading session.
• BSX shares have outperformed the Medical sector and the S&P 500 over the past month, despite a 5.44% decrease.
• Anticipated earnings report on April 23, 2025, expects an EPS of $0.67 and revenue of $4.56 billion, highlighting significant year-over-year growth.

Boston Scientific Corporation, listed on the NYSE under the symbol BSX, is a prominent player in the medical device industry. The company specializes in developing and manufacturing a wide range of medical solutions, including devices for cardiology, endoscopy, and urology. Boston Scientific competes with other major medical device companies like Medtronic and Johnson & Johnson.

On April 18, 2025, Citigroup reaffirmed its "Outperform" rating for BSX, with the stock priced at $95.12. This rating suggests that Citigroup expects BSX to perform better than the overall market. Despite this positive outlook, BSX experienced a slight decline of 0.14% in its latest trading session, closing at $95.12. This contrasts with the S&P 500's gain of 0.13%.

Over the past month, BSX shares have decreased by 5.44%. However, this performance is relatively strong compared to the Medical sector's loss of 8.46% and the S&P 500's decline of 6.3%. Investors are eagerly anticipating Boston Scientific's upcoming earnings report on April 23, 2025. The company is expected to report an EPS of $0.67, a 19.64% increase from the same quarter last year.

Revenue for Boston Scientific is anticipated to reach $4.56 billion, marking an 18.2% rise compared to the previous year. The stock has fluctuated between $94.70 and $96.06 today, with a 52-week high of $107.17 and a low of $66.80. BSX's market capitalization is approximately $140.7 billion, with a trading volume of 6.67 million shares.